Results 121 to 127 of about 14,652 (127)

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

New England Journal of Medicine, 2015
Bernard Zinman Cm, Christoph Wanner, John M Lachin   +2 more
exaly  

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

New England Journal of Medicine, 2016
Christoph Wanner, John M Lachin, David H Fitchett   +2 more
exaly  

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care

Circulation, 2019
Elisabetta Patorno, Ajinkya Pawar, Jessica M Franklin   +2 more
exaly  

Empagliflozin

Reactions Weekly, 2017
  +4 more sources

Empagliflozin after Acute Myocardial Infarction

New England Journal of Medicine
josephineharrington Harrington, Tomasz Gasior, Xavier Rossello   +2 more
exaly  

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

Lancet, The
exaly  

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease

New England Journal of Medicine
exaly